Prior studies have shown that patients with seropositive rheumatoid arthritis (RA) In 1975, Alspaugh and Tan reported the discovery of an antibody in patients with seropositive rheumatoid arthritis (RA) that precipitated with extracts of human B lymphoblastoid cell lines containing the genome of the Epstein-Barr virus (EBV) (1). It was shown by indirect immunofluorescence that the antigen was confined primarily to the cell nucleus, and the antigen was therefore designated the rheumatoid arthritis nuclear antigen (RANA) (2). RANA is closely related to another nuclear antigen, the Epstein-Barr nuclear antigen (EBNA), detected by anticomplement immunofluorescence (3). RANA and EBNA seem to be biochemically dissimilar by their differing solubilities in ammonium sulfate and different susceptibilities to digestion by the enzyme deoxyribonuclease (1, 4). Individual sera have been found with antibodies exclusively to one or the other (1, 2). RANA and EBNA are B cell neoantigens distinct from the viral capsid antigen (VCA) present in the virion of the EBV (5).
association between the presence of antibodies to RA nuclear antigen and the titers of antibody to Epstein-Barr nuclear antigen. Thus, normal subjects with antibody to RA nuclear antigen had titers of antibody to Epstein-Barr nuclear antigen equivalent to those of patients with RA and significantly higher than normal subjects lacking antibody to RA nuclear antigen. One interpretation of these results is that patients with seropositive RA derive from a larger population with enhanced immune responsiveness to B lymphocyte nuclear antigens determined by the Epstein-Barr virus. In 1975, Alspaugh and Tan reported the discovery of an antibody in patients with seropositive rheumatoid arthritis (RA) that precipitated with extracts of human B lymphoblastoid cell lines containing the genome of the Epstein-Barr virus (EBV) (1) . It was shown by indirect immunofluorescence that the antigen was confined primarily to the cell nucleus, and the antigen was therefore designated the rheumatoid arthritis nuclear antigen (RANA) (2) . RANA is closely related to another nuclear antigen, the Epstein-Barr nuclear antigen (EBNA), detected by anticomplement immunofluorescence (3) . RANA and EBNA seem to be biochemically dissimilar by their differing solubilities in ammonium sulfate and different susceptibilities to digestion by the enzyme deoxyribonuclease (1, 4) . Individual sera have been found with antibodies exclusively to one or the other (1, 2). RANA and EBNA are B cell neoantigens distinct from the viral capsid antigen (VCA) present in the virion of the EBV (5) .
Previous serologic studies (6) (7) (8) found no evidence for a role for EBV in RA. Comparable titers of antibody to VCA were found in normal individuals and RA patients (6) (7) (8) , and no evidence of increased anti-VCA was found in RA synovial effusions relative to paired RA sera (9) . The findings by Alspaugh et al. (1, 2) of the high frequency of anti-RANAt in RA, however, raised anew the question of a role for EBV. The aim of our study was (i) to investigate in normal individuals positive and negative for anti-RANA the titers of antibodies to EBNA and (ii) to determine the anti-EBNA titers in RA and normal persons.
MATERIALS AND METHODS Sera. Forty-seven sera were obtained from patients with classical or definite RA, all seropositive by latex fixation testing (titer 80 or greater). Sera were also obtained from 48 normal subjects and from 21 patients who fulfilled the provisional criteria for systemic lupus erythematosus (SLE) (10 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. Assay for Anti-RANA. Anti-RANA was detected by a modification of the double radial immunodiffusion technique of Alspaugh and Tan (1). Twenty-five by 75 mm glass slides were layered with 3.25 ml of 1% agarose in phosphate-buffered saline (pH 7.4). The wells were 3 mm in diameter and 2.5 mm apart. Reactions proceeded at 40C and precipitin lines were read over a period of 72 hr. Test sera were placed in wells adjacent to a reference serum in order to establish identity or nonidentity between precipitin lines of the test sera and the reference serum.
Assay for Anti-EBNA. Wil-2 cells were used as the substrate in a modification of the anti-complement immunofluorescence technique for demonstration of antibodies of EBNA, as described by Reedman and Klein (3) . In brief, Wil-2 cells washed in phosphate-buffered saline are cytocentrifuged onto microscope slides, fixed with acetone for 2 min, overlaid with serially diluted sera, incubated 30 min at room temperature in a moist chamber, washed, exposed to complement (1:10 fresh normal human serum devoid of anti-EBV antibodies) for 30 min at room temperature, washed, and stained with fluorescein-conjugated goat anti-C3 (Meloy Laboratories, Springfield, VA). In our hands, this method produces more stable cell preparations then the original method of Reedman and Klein (3) and comparable results. Known positive and negative control sera were titered with each set of test sera and yielded reproducible titers. All slides were read independently and blindly by at least two observers. Titers of both anti-EBNA and anti-VCA antibodies are expressed as the highest serum dilution yielding detectable immunofluorescence. The immunofluorescence titers for either anti-EBNA or anti-VCA (below) never differed by more than one tube and were identical 90% of the time both between observers for the same assay and on several occasions when assays were repeated.
Preparations of the EBV genome-negative T lymphoblastoid cell line CCRF-CEM (11) Collection) (14) . The radioimmunoassays were performed as recently described (15) , using a specially designed immuno- ml of serum had been absorbed with 0.5-1.0 ml of packed gel overnight at 40C, the eluate was consistently depleted of rheumatoid factor (latex fixation titer <1:10).
Statistics. Anti-RANA frequencies of the normal and the patient groups were compared by the x2 method, as were male-to-female ratios. Antibody titers were compared by the Wilcoxon ranks sums method, as were ages. Linear regression was used to test for correlations between anti-EBNA titers and ages (17) . RESULTS Anti-RANA. Twelve out of 48 (25%) normal sera were positive for anti-RANA at 72 hr compared to 44 of 47 (94%) sera of patients with seropositive RA, a difference in frequency that was highly significant (P < 10-10) ( Removal of rheumatoid factor from five RA sera resulted in no appreciable change in anti-RANA titers (Table 2) .
Anti-EBNA. As a group, the normal subjects had significantly lower anti-EBNA titers than did the RA patients (P < 0.001), with geometric mean titers of 11 and 40, respectively (Fig. 1) . The anti-EBNA titers of anti-RANA-negative and anti-RANA-positive normals were also significantly different (P < 0.002), with geometric mean titers of 7.2 and 47, respectively.
The anti-RANA-positive normals thus had anti-EBNA titers comparable to those of the RA patients.
As was the case with anti-RANA, removal of rheumatoid factor did not appreciably change the anti-EBNA titers of five RA sera (Table 2) .
Anti-VCA. In contrast to the anti-EBNA results, normals and RA patients had comparable titers (P = 0.60) of anti-VCA, as did anti-RANA-negative and anti-RANA-positive normals (P = 0.40) (Fig. 2) .
Antibodies to Other Human Herpesviruses. Three groups of sera were titered for antibodies to HSV, VZV, and CMV by radioimmunoassay: 6 anti-RANA-negative normal sera with the lowest anti-EBNA titers; 6 anti-RANA-positive normal sera with the highest anti-EBNA titers; and 10 anti-RANA-positive RA sera with the highest anti-EBNA titers ( Table 3 ). The same sera were also assayed for complement-fixing antibodies to HSV (Table 3) . Finally, 12 anti-RANA-negative normal sera, 12 anti-RANA-positive normal sera, and 16 anti-RANA-positive RA sera were assayed from neutralizing antibodies to HSV (Table 4) . No significant differences among the groups were found by any of the assays. In vitro, the development of EBNA and RANA in human B lymphocytes is associated not only with transformation but also with polyclonal B cell activation. The latter can include rheumatoid factor production by lymphocytes from both normal individuals and from RA patients, but more so from the RA patients (21) .
It is possible that the subset of normal persons with altered reactivity to EBV-determined nuclear antigens includes those individuals who are destined to develop seropositive RA. To what extent these antibodies do indeed represent a risk factor for the development of the RA may be estimated by identifying populations of stored sera in which anti-RANA and anti-EBNA antibodies can be determined in the premorbid state of persons who subsequently develop RA.
